• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3.

作者信息

Hirata Michinori, Katsumata Kyoko, Endo Koichi, Fukushima Naoshi, Ohkawa Hiroyuki, Fukagawa Masafumi

机构信息

Fuji Gotemba Research Labs, Chugai Pharmaceutical Co., Ltd, Shizuoka, Japan.

出版信息

Nephrol Dial Transplant. 2003 Sep;18(9):1770-6. doi: 10.1093/ndt/gfg296.

DOI:10.1093/ndt/gfg296
PMID:12937223
Abstract

BACKGROUND

Although it effectively suppresses parathyroid hormone (PTH) secretion, vitamin D [1,25(OH)(2)D(3)] therapy often causes tissue calcification over the long term. In patients on chronic dialysis, cardiovascular calcification is clearly linked to an unfavourable prognosis. In pre-dialysis patients, renal calcification of the kidney leads to the deterioration of renal function.

METHODS

We compared the propensities of 22-oxacalcitriol (OCT), with lesser calcaemic action, and 1,25(OH)(2)D(3) for producing their potential side effects in rats: (i) metastatic calcification of heart and aorta, and (ii) renal dysfunction with nephrocalcinosis, using the same effective doses for hyperparathyroidism. OCT (1.25 and 6.25 micro g/kg) or 1,25(OH)(2)D(3) (0.125 and 0.625 micro g/kg) solutions were administered intravenously to subtotally nephrectomized (SNX) rats three times weekly for 2 weeks.

RESULTS

Despite the suppression of PTH to comparable levels, the calcification of the hearts, aortas and kidneys in the 1,25(OH)(2)D(3)-treated group was significantly greater than in the OCT-treated group. Of interest was that, in the OCT (6.25 micro g/kg) group, the degree of calcification in hearts, aortas and kidneys were distinctly lower than those in the 1,25(OH)(2)D(3) (0.125 micro g/kg) group despite the comparable serum Ca x Pi products. Therefore, there may be different mechanisms behind the calcifications resulting from OCT and 1,25(OH)(2)D(3). Deterioration of renal function, tubular changes, and atypical hyperplasia of proximal tubules associated with calcification were more severe in the 1,25(OH)(2)D(3)-treated group than in the OCT-treated group.

CONCLUSIONS

These results indicate that OCT may be an effective agent for the suppression of PTH with a lesser risk of cardiovascular calcification or deterioration of residual renal function.

摘要

相似文献

1
In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3.
Nephrol Dial Transplant. 2003 Sep;18(9):1770-6. doi: 10.1093/ndt/gfg296.
2
A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action.1,25-二羟基-22-氧维生素D(3)与1,25-二羟基维生素D(3)在抑制甲状旁腺激素分泌及血钙作用方面的比较
Nephrol Dial Transplant. 2002;17 Suppl 10:41-5. doi: 10.1093/ndt/17.suppl_10.41.
3
A comparison between daily and thrice-weekly i.v. administration of 1,25-dihydroxy-22-oxavitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action in uraemic rats.
Nephrol Dial Transplant. 2002;17 Suppl 10:37-40. doi: 10.1093/ndt/17.suppl_10.37.
4
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.1α(OH)D3 一α-羟基胆钙化醇——一种活性维生素 D 类似物。关于慢性透析的尿毒症患者继发性甲状旁腺功能亢进症预防和治疗的临床研究。
Dan Med Bull. 2008 Nov;55(4):186-210.
5
22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.22-氧杂骨化三醇可抑制肾衰竭犬的继发性甲状旁腺功能亢进,且不会导致低骨转换。
Kidney Int. 1999 Mar;55(3):821-32. doi: 10.1046/j.1523-1755.1999.055003821.x.
6
[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].3、4、5期慢性肾脏病(未透析)患者矿物质代谢的变化
Nefrologia. 2008;28 Suppl 3:67-78.
7
The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.维生素D的非钙调节类似物,22-氧杂骨化三醇,可抑制甲状旁腺激素的合成与分泌。
J Clin Invest. 1989 Sep;84(3):728-32. doi: 10.1172/JCI114229.
8
Effects of i.v. and oral 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in dogs with chronic renal failure.静脉注射和口服1,25 - 二羟基 - 22 - 氧维生素D(3)对慢性肾衰竭犬继发性甲状旁腺功能亢进的影响。
Nephrol Dial Transplant. 2002;17 Suppl 10:46-52. doi: 10.1093/ndt/17.suppl_10.46.
9
22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats.22-氧代骨化三醇可预防次全肾切除大鼠的进行性肾小球硬化,且不会对钙磷代谢产生不利影响。
Nephrol Dial Transplant. 2002 Dec;17(12):2132-7. doi: 10.1093/ndt/17.12.2132.
10
22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis.22-氧杂骨化三醇改善缓慢进展性肾炎大鼠的高转换骨及显著的纤维性骨炎。
Kidney Int. 1999 Dec;56(6):2040-7. doi: 10.1046/j.1523-1755.1999.00772.x.

引用本文的文献

1
Development of animal models with chronic kidney disease-mineral and bone disorder based on clinical characteristics and pathogenesis.基于临床特征和发病机制的慢性肾脏病-矿物质和骨异常动物模型的建立
Front Endocrinol (Lausanne). 2025 Mar 25;16:1549562. doi: 10.3389/fendo.2025.1549562. eCollection 2025.
2
Vascular Calcification in Rodent Models-Keeping Track with an Extented Method Assortment.啮齿动物模型中的血管钙化——采用多种扩展方法进行追踪
Biology (Basel). 2021 May 22;10(6):459. doi: 10.3390/biology10060459.
3
Vitamin D and Glomerulonephritis.
维生素 D 与肾小球肾炎。
Medicina (Kaunas). 2021 Feb 22;57(2):186. doi: 10.3390/medicina57020186.
4
Research Models for Studying Vascular Calcification.研究血管钙化的模型。
Int J Mol Sci. 2020 Mar 23;21(6):2204. doi: 10.3390/ijms21062204.
5
Supplementary nutrients for prevention of vascular calcification in patients with chronic kidney disease.用于预防慢性肾脏病患者血管钙化的补充营养素。
Korean J Intern Med. 2019 May;34(3):459-469. doi: 10.3904/kjim.2019.125. Epub 2019 Apr 30.
6
Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation.慢性肾脏病和终末期肾病患者的矿物质与骨代谢紊乱:维生素D受体激活的新见解
Kidney Int Suppl (2011). 2011 Sep;1(4):122-129. doi: 10.1038/kisup.2011.28.
7
Active vitamin D and accelerated progression of aortic stiffness in hemodialysis patients: a longitudinal observational study.活性维生素D与血液透析患者主动脉僵硬度加速进展:一项纵向观察性研究。
Am J Hypertens. 2014 Nov;27(11):1346-54. doi: 10.1093/ajh/hpu057. Epub 2014 Apr 2.
8
Experimental models of renal disease and the cardiovascular system.肾脏疾病与心血管系统的实验模型
Open Cardiovasc Med J. 2010 Nov 26;4:257-64. doi: 10.2174/1874192401004010257.
9
Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels.严重慢性肾脏病的血管钙化和继发性甲状旁腺功能亢进及其与血清磷和钙水平的关系。
Br J Pharmacol. 2009 Apr;156(8):1267-78. doi: 10.1111/j.1476-5381.2008.00108.x. Epub 2009 Mar 19.
10
A rat model of chronic kidney disease-mineral bone disorder.慢性肾脏病-矿物质和骨异常大鼠模型
Kidney Int. 2009 Jan;75(2):176-84. doi: 10.1038/ki.2008.456. Epub 2008 Sep 17.